Forum report: Issues in the evaluation of diagnostic tests, use of historical controls, and merits of the current multicenter collaborative groups

John E. Bennett, Carol Kauffman, Thomas Walsh, Ben De Pauw, William Dismukes, John N Galgiani, Michel Glauser, Raoul Herbrecht, Jeannette Lee, Peter Pappas, John Powers, John Rex, Paul Verweij, Claudio Viscoli

Research output: Contribution to journalArticle

10 Citations (Scopus)

Abstract

This forum report contains conclusions about 3 different issues relevant to conducting clinical trials in deep mycoses. (1) Trials of diagnostic tests for deep mycoses must define the population appropriate for testing and the clinical question being asked. The unanswered question for the serum Aspergillus galactomannan assay is whether knowledge of results can change use of empirical therapy to treat febrile patients at high risk of invasive aspergillosis. (2) Use of historical controls is suboptimal but offers a pragmatic solution for studying rare mycoses; use of contemporaneous controls, matched for critical variables and evaluated by a blinded data review committee using detailed criteria, appears optimal. (3) Established groups of independent investigators, such as the European Organization for Research on Treatment of Cancer's Invasive Fungal Infections Group and National Institute of Allergy and Infectious Diseases's Bacteriology and Mycology Study Group, provide a pool of experienced investigators, defined operating rules, impartiality, and specialized expertise. Considering the enormous investment required for adequately powered efficacy trials of antifungal agents and the importance of these trials to guide clinical practice, use of collaborative groups outweighs the extra administrative time that is sometimes required.

Original languageEnglish (US)
JournalClinical Infectious Diseases
Volume36
Issue numberSUPPL. 3
DOIs
StatePublished - Apr 15 2003

Fingerprint

Mycoses
Routine Diagnostic Tests
National Institute of Allergy and Infectious Diseases (U.S.)
Research Personnel
Mycology
Bacteriology
Aspergillosis
Antifungal Agents
Advisory Committees
Aspergillus
Fever
Clinical Trials
Organizations
Therapeutics
Serum
Research
Population
Neoplasms

ASJC Scopus subject areas

  • Immunology

Cite this

Forum report : Issues in the evaluation of diagnostic tests, use of historical controls, and merits of the current multicenter collaborative groups. / Bennett, John E.; Kauffman, Carol; Walsh, Thomas; De Pauw, Ben; Dismukes, William; Galgiani, John N; Glauser, Michel; Herbrecht, Raoul; Lee, Jeannette; Pappas, Peter; Powers, John; Rex, John; Verweij, Paul; Viscoli, Claudio.

In: Clinical Infectious Diseases, Vol. 36, No. SUPPL. 3, 15.04.2003.

Research output: Contribution to journalArticle

Bennett, JE, Kauffman, C, Walsh, T, De Pauw, B, Dismukes, W, Galgiani, JN, Glauser, M, Herbrecht, R, Lee, J, Pappas, P, Powers, J, Rex, J, Verweij, P & Viscoli, C 2003, 'Forum report: Issues in the evaluation of diagnostic tests, use of historical controls, and merits of the current multicenter collaborative groups', Clinical Infectious Diseases, vol. 36, no. SUPPL. 3. https://doi.org/10.1086/367840
Bennett, John E. ; Kauffman, Carol ; Walsh, Thomas ; De Pauw, Ben ; Dismukes, William ; Galgiani, John N ; Glauser, Michel ; Herbrecht, Raoul ; Lee, Jeannette ; Pappas, Peter ; Powers, John ; Rex, John ; Verweij, Paul ; Viscoli, Claudio. / Forum report : Issues in the evaluation of diagnostic tests, use of historical controls, and merits of the current multicenter collaborative groups. In: Clinical Infectious Diseases. 2003 ; Vol. 36, No. SUPPL. 3.
@article{1dfde20724ca4f5ea643e664630cc467,
title = "Forum report: Issues in the evaluation of diagnostic tests, use of historical controls, and merits of the current multicenter collaborative groups",
abstract = "This forum report contains conclusions about 3 different issues relevant to conducting clinical trials in deep mycoses. (1) Trials of diagnostic tests for deep mycoses must define the population appropriate for testing and the clinical question being asked. The unanswered question for the serum Aspergillus galactomannan assay is whether knowledge of results can change use of empirical therapy to treat febrile patients at high risk of invasive aspergillosis. (2) Use of historical controls is suboptimal but offers a pragmatic solution for studying rare mycoses; use of contemporaneous controls, matched for critical variables and evaluated by a blinded data review committee using detailed criteria, appears optimal. (3) Established groups of independent investigators, such as the European Organization for Research on Treatment of Cancer's Invasive Fungal Infections Group and National Institute of Allergy and Infectious Diseases's Bacteriology and Mycology Study Group, provide a pool of experienced investigators, defined operating rules, impartiality, and specialized expertise. Considering the enormous investment required for adequately powered efficacy trials of antifungal agents and the importance of these trials to guide clinical practice, use of collaborative groups outweighs the extra administrative time that is sometimes required.",
author = "Bennett, {John E.} and Carol Kauffman and Thomas Walsh and {De Pauw}, Ben and William Dismukes and Galgiani, {John N} and Michel Glauser and Raoul Herbrecht and Jeannette Lee and Peter Pappas and John Powers and John Rex and Paul Verweij and Claudio Viscoli",
year = "2003",
month = "4",
day = "15",
doi = "10.1086/367840",
language = "English (US)",
volume = "36",
journal = "Clinical Infectious Diseases",
issn = "1058-4838",
publisher = "Oxford University Press",
number = "SUPPL. 3",

}

TY - JOUR

T1 - Forum report

T2 - Issues in the evaluation of diagnostic tests, use of historical controls, and merits of the current multicenter collaborative groups

AU - Bennett, John E.

AU - Kauffman, Carol

AU - Walsh, Thomas

AU - De Pauw, Ben

AU - Dismukes, William

AU - Galgiani, John N

AU - Glauser, Michel

AU - Herbrecht, Raoul

AU - Lee, Jeannette

AU - Pappas, Peter

AU - Powers, John

AU - Rex, John

AU - Verweij, Paul

AU - Viscoli, Claudio

PY - 2003/4/15

Y1 - 2003/4/15

N2 - This forum report contains conclusions about 3 different issues relevant to conducting clinical trials in deep mycoses. (1) Trials of diagnostic tests for deep mycoses must define the population appropriate for testing and the clinical question being asked. The unanswered question for the serum Aspergillus galactomannan assay is whether knowledge of results can change use of empirical therapy to treat febrile patients at high risk of invasive aspergillosis. (2) Use of historical controls is suboptimal but offers a pragmatic solution for studying rare mycoses; use of contemporaneous controls, matched for critical variables and evaluated by a blinded data review committee using detailed criteria, appears optimal. (3) Established groups of independent investigators, such as the European Organization for Research on Treatment of Cancer's Invasive Fungal Infections Group and National Institute of Allergy and Infectious Diseases's Bacteriology and Mycology Study Group, provide a pool of experienced investigators, defined operating rules, impartiality, and specialized expertise. Considering the enormous investment required for adequately powered efficacy trials of antifungal agents and the importance of these trials to guide clinical practice, use of collaborative groups outweighs the extra administrative time that is sometimes required.

AB - This forum report contains conclusions about 3 different issues relevant to conducting clinical trials in deep mycoses. (1) Trials of diagnostic tests for deep mycoses must define the population appropriate for testing and the clinical question being asked. The unanswered question for the serum Aspergillus galactomannan assay is whether knowledge of results can change use of empirical therapy to treat febrile patients at high risk of invasive aspergillosis. (2) Use of historical controls is suboptimal but offers a pragmatic solution for studying rare mycoses; use of contemporaneous controls, matched for critical variables and evaluated by a blinded data review committee using detailed criteria, appears optimal. (3) Established groups of independent investigators, such as the European Organization for Research on Treatment of Cancer's Invasive Fungal Infections Group and National Institute of Allergy and Infectious Diseases's Bacteriology and Mycology Study Group, provide a pool of experienced investigators, defined operating rules, impartiality, and specialized expertise. Considering the enormous investment required for adequately powered efficacy trials of antifungal agents and the importance of these trials to guide clinical practice, use of collaborative groups outweighs the extra administrative time that is sometimes required.

UR - http://www.scopus.com/inward/record.url?scp=0037447155&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0037447155&partnerID=8YFLogxK

U2 - 10.1086/367840

DO - 10.1086/367840

M3 - Article

C2 - 12679896

AN - SCOPUS:0037447155

VL - 36

JO - Clinical Infectious Diseases

JF - Clinical Infectious Diseases

SN - 1058-4838

IS - SUPPL. 3

ER -